Investor Presentation H1 2023
90
Investor presentation
First six months of 2023
In the phase 1/2 trial, Mim8 appeared to have a well tolerated
safety profile and read out with exploratory efficacy
Patients with bleeds per cohort
Low number of patients with treated bleeds after cohort 1
10
N=7
N=9
N=8
N=8
N=10
•
9
028765432-0
Cohort 1
1.2mg QW
Cohort 5
35mg QW
Cohort 2
3.8mg QW
Cohort 3
15mg QW
Cohort 4
60mg QM
# Patients with 0 bleeds
# Patients with 1 bleed
#Patients with >2 bleeds
•
Mim8 safety characteristics
Adverse events
No dose-dependency on rates, causality, type
or severity of adverse events
No thromboembolic events
Three serious AEs deemed unrelated to trial
product and two hypersensitivity reactions
Injection site reactions in only 1% of injections
(6 events of ~600 injections given)
Anti-Mim8 antibodies
No occurrence of anti-Mim8 antibodies
detected
Exploratory analysis implied that >70% of patients enrolled had no bleeds in the 12 weeks
Overall, no safety concern observed
QW: Once-weekly, QM: Once-monthly, N=Number of patients, AE: Adverse event
Novo NordiskⓇView entire presentation